Exhaustive criteria and definitive data to identify the ideal lung oligometastatic patient as a candidate for stereotactic body radiotherapy (SBRT) are lacking. Three distinct cohorts of oligometastatic patients could be distinguished: (1) patients with upfront diagnosis of oligometastases (synchronous or metachronous); (2) patients with oligorecurrent disease in terms of relapsed oligometastatic phase; (3) oligoprogressive patients after cytoreductive treatment. The aim of the present review is to analyze available data concerning the efficacy/safety of SBRT for oligometastatic/oligoprogressive/oligorecurrent lung metastases.
ShultzDBFilippiARThariatJet al. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. J Thorac Oncol2014; 9: 1426–1433.
5.
AslamSEmmanuelP.Formulating a researchable question: a critical step for facilitating good clinical research. Indian J Sex Transm Dis2010; 31: 47–50.
6.
OstiMFCarnevaleAValerianiMet al. Clinical outcomes of single dose stereotactic radiotherapy for lung metastases. Clin Lung Cancer2013; 14: 699–703.
7.
BaschnagelAMMangonaVSRobertsonJMet al. Lung metastases treated with image-guided stereotactic body radiation therapy. Clin Oncol2013; 25: 236–241.
8.
NavarriaPAscoleseAMTomatisSet al. Stereotactic body radiotherapy in lung oligometastatic patients: role of local treatments. Radiat Oncol2014; 9: 91.
9.
RusthovenKEKavanaghBDBurriSHet al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol2009; 27: 1579–1584.
10.
AokiMHatayamaYKawaguchiHet al. Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study. J Radiat Res2016; 57: 55–61.
11.
NorihisaYNagataYTakayamaKet al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys2008; 72: 398–403.
12.
PasqualettiFMontroneSVivaldiCet al. Stereotactic body radiotherapy in patients with lung oligometastases from colorectal cancer. Anticancer Res2017; 37: 315–319.
13.
OhDAhnYCSeoJMet al. Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. Acta Oncol2012; 51: 596–602.
14.
TakahashiWYamashitaHNiibeYet al. Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases. Pulm Med2012; 2012: 454107.
15.
YamashitaHNiibeYYamamotoTet al. Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases. Jpn J Clin Oncol2016; 46: 687–691.
16.
NiibeYYamashitaHSekiguchiKet al. Stereotactic body radiotherapy results for pulmonary oligometastases: a two-institution collaborative investigation. Anticancer Res2015; 35: 4903–4908.
17.
WidderJKlinkenbergTJUbbelsJFWiegmanEMGroenHJLangendijkJA.Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?Radiother Oncol2013; 107: 409–413.
18.
BaumannBCNagdaSNKolkerJDet al. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: a potential alternative to resection. J Surg Oncol2016; 114: 65–69.
19.
BinkleyMSTrakulNJacobsLRet al. Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys2015; 92: 1044–1052.
20.
HelouJThibaultIPoonIet al. Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter. Int J Radiat Oncol Biol Phys2017; 98: 419–427.
21.
FilippiARBadellinoSCeccarelliMet al. Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study. Int J Radiat Oncol Biol Phys2015; 91: 524–529.
22.
RicardiUFilippiARGuarneriAet al. Stereotactic body radiation therapy for lung metastases. Lung Cancer2012; 75: 77–81.
23.
TakedaASanukiNTsurugaiY.et al. Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83–100 Gy in five fractions. J Radiat Res2016; 57: 400–405.
24.
MazzolaRFiorentinoARicchettiFet al. Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response. Br J Radiol2016; 20: 20160146.
25.
MilanoMTKatzAWZhangHet al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys2012; 83: 878–886.
26.
PastorinoUBuyseMFriedelGet al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg1997; 113: 37–49.
27.
de BaèreTAupérinADeschampsFet al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol2015; 26: 987–991.
28.
AshworthABSenanSPalmaDAet al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer2014; 15: 346–355.
29.
GuckenbergerMKlementRJAllgäuerMet al. Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol2016; 118: 485–491.
30.
MazzolaRTebanoUAielloDet al. Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer. Tumori Epub 2017 Dec 13. DOI: 10.5301/tj.5000701.
